BTIG Upgrades Juno Therapeutics (JUNO) to Neutral

November 4, 2016 7:17 AM EDT
Get Alerts JUNO Hot Sheet
Price: $20.43 +2.66%

Rating Summary:
    9 Buy, 5 Hold, 0 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 11 | Down: 31 | New: 42
Trade JUNO Now!
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

BTIG upgraded Juno Therapeutics (NASDAQ: JUNO) from Sell to Neutral.

Analyst Dane Leone said, "We upgrade shares of Juno to Neutral from Sell, as the stock price has hit our target price and the ASH abstract release showed similar response rates for JCAR017 versus Kite’s (KITE, Neutral) KTE-C19 in the treatment of patients with Diffuse Large B-Cell Lymphoma. We continue to think that Sell-side estimates for the CD19 CAR T class are too high, but acknowledge that Buy-side expectations are more inline with our model."

For an analyst ratings summary and ratings history on Juno Therapeutics click here. For more ratings news on Juno Therapeutics click here.

Shares of Juno Therapeutics closed at $22.72 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments, Upgrades

Related Entities

BTIG

Add Your Comment